Travere Therapeutics Inc (TVTX)

NASDAQ
22.53
+0.44(+1.99%)
  • Volume:
    554,129
  • Day's Range:
    21.71 - 22.70
  • 52 wk Range:
    17.97 - 30.35

TVTX Overview

Prev. Close
22.09
Day's Range
21.71-22.7
Revenue
159.24M
Open
22.42
52 wk Range
17.97-30.35
EPS
-4.19
Volume
554,129
Market Cap
1.45B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
848,739
P/E Ratio
-5.34
Beta
0.507
1-Year Change
-16.7%
Shares Outstanding
64,173,570
Next Earnings Date
Feb 28, 2023
What is your sentiment on Travere Therapeutics?
or
Vote to see community's results!

Travere Therapeutics Inc News

Travere Therapeutics Inc Analysis

Travere Therapeutics Inc Company Profile

Travere Therapeutics Inc Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuyStrong BuySell
Technical IndicatorsBuyStrong SellStrong BuyStrong BuyStrong Sell
SummaryNeutralNeutralStrong BuyStrong BuyStrong Sell